866-997-4948(US-Canada Toll Free)

Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Dec 2016

Category :

Pharmaceutical

No. of Pages : 1321 Pages

Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Glioblastoma Multiforme (GBM) Pipeline Review, H2 2016, provides an overview of the Glioblastoma Multiforme (GBM) (Oncology) pipeline landscape.

Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor. GBMs arise from glial cells, which are cells that form the tissue that surrounds and protects other nerve cells found within the brain and spinal cord. GBMs are mainly composed of star-shaped glial cells known as astrocytes. Signs and symptoms include slowly progressive neurologic deficit, usually motor weakness, headache, generalized symptoms of increased intracranial pressure, including headaches, nausea and vomiting, and cognitive impairment and seizures. Treatment includes radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Glioblastoma Multiforme (GBM) Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Glioblastoma Multiforme (GBM) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Glioblastoma Multiforme (GBM) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Glioblastoma Multiforme (GBM) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 11, 98, 53, 1, 4, 147, 18 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 8, 12, 1, 35 and 8 molecules, respectively.

Glioblastoma Multiforme (GBM) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Glioblastoma Multiforme (GBM) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Glioblastoma Multiforme (GBM) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Glioblastoma Multiforme (GBM) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Glioblastoma Multiforme (GBM) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Glioblastoma Multiforme (GBM) (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Glioblastoma Multiforme (GBM) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Glioblastoma Multiforme (GBM) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
Introduction 10
Glioblastoma Multiforme (GBM) Overview 11
Therapeutics Development 12
Glioblastoma Multiforme (GBM) - Therapeutics under Development by Companies 14
Glioblastoma Multiforme (GBM) - Therapeutics under Investigation by Universities/Institutes 32
Glioblastoma Multiforme (GBM) - Pipeline Products Glance 35
Glioblastoma Multiforme (GBM) - Products under Development by Companies 39
Glioblastoma Multiforme (GBM) - Products under Investigation by Universities/Institutes 61
Glioblastoma Multiforme (GBM) - Companies Involved in Therapeutics Development 65
Glioblastoma Multiforme (GBM) - Therapeutics Assessment 260
Drug Profiles 302
Glioblastoma Multiforme (GBM) - Dormant Projects 1242
Glioblastoma Multiforme (GBM) - Discontinued Products 1259
Glioblastoma Multiforme (GBM) - Product Development Milestones 1262
Appendix 1278

List of Tables
Number of Products under Development for Glioblastoma Multiforme (GBM), H2 2016 54
Number of Products under Development for Glioblastoma Multiforme (GBM) - Comparative Analysis, H2 2016 55
Number of Products under Development by Companies, H2 2016 57
Number of Products under Development by Companies, H2 2016 (Contd..1) 58
Number of Products under Development by Companies, H2 2016 (Contd..2) 59
Number of Products under Development by Companies, H2 2016 (Contd..3) 60
Number of Products under Development by Companies, H2 2016 (Contd..4) 61
Number of Products under Development by Companies, H2 2016 (Contd..5) 62
Number of Products under Development by Companies, H2 2016 (Contd..6) 63
Number of Products under Development by Companies, H2 2016 (Contd..7) 64
Number of Products under Development by Companies, H2 2016 (Contd..8) 65
Number of Products under Development by Companies, H2 2016 (Contd..9) 66
Number of Products under Development by Companies, H2 2016 (Contd..10) 67
Number of Products under Development by Companies, H2 2016 (Contd..11) 68
Number of Products under Development by Companies, H2 2016 (Contd..12) 69
Number of Products under Development by Companies, H2 2016 (Contd..13) 70
Number of Products under Development by Companies, H2 2016 (Contd..14) 71
Number of Products under Development by Companies, H2 2016 (Contd..15) 72
Number of Products under Development by Companies, H2 2016 (Contd..16) 73
Number of Products under Investigation by Universities/Institutes, H2 2016 74
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 75
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 76
Comparative Analysis by Late Stage Development, H2 2016 77
Comparative Analysis by Clinical Stage Development, H2 2016 78
Comparative Analysis by Early Stage Development, H2 2016 79
Comparative Analysis by Unknown Stage Development, H2 2016 80
Products under Development by Companies, H2 2016 81
Products under Development by Companies, H2 2016 (Contd..1) 82
Products under Development by Companies, H2 2016 (Contd..2) 83
Products under Development by Companies, H2 2016 (Contd..3) 84
Products under Development by Companies, H2 2016 (Contd..4) 85
Products under Development by Companies, H2 2016 (Contd..5) 86
Products under Development by Companies, H2 2016 (Contd..6) 87
Products under Development by Companies, H2 2016 (Contd..7) 88
Products under Development by Companies, H2 2016 (Contd..8) 89
Products under Development by Companies, H2 2016 (Contd..9) 90
Products under Development by Companies, H2 2016 (Contd..10) 91
Products under Development by Companies, H2 2016 (Contd..11) 92
Products under Development by Companies, H2 2016 (Contd..12) 93
Products under Development by Companies, H2 2016 (Contd..13) 94
Products under Development by Companies, H2 2016 (Contd..14) 95
Products under Development by Companies, H2 2016 (Contd..15) 96
Products under Development by Companies, H2 2016 (Contd..16) 97
Products under Development by Companies, H2 2016 (Contd..17) 98
Products under Development by Companies, H2 2016 (Contd..18) 99
Products under Development by Companies, H2 2016 (Contd..19) 100
Products under Development by Companies, H2 2016 (Contd..20) 101
Products under Development by Companies, H2 2016 (Contd..21) 102
Products under Investigation by Universities/Institutes, H2 2016 103
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 104
Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 105
Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 106
Glioblastoma Multiforme (GBM) - Pipeline by AbbVie Inc, H2 2016 107
Glioblastoma Multiforme (GBM) - Pipeline by Activartis Biotech GmbH, H2 2016 108
Glioblastoma Multiforme (GBM) - Pipeline by Advanced Accelerator Applications SA, H2 2016 109
Glioblastoma Multiforme (GBM) - Pipeline by Advantagene Inc, H2 2016 110
Glioblastoma Multiforme (GBM) - Pipeline by Advenchen Laboratories LLC, H2 2016 111
Glioblastoma Multiforme (GBM) - Pipeline by Affimed GmbH, H2 2016 112
Glioblastoma Multiforme (GBM) - Pipeline by Agenus Inc, H2 2016 113
Glioblastoma Multiforme (GBM) - Pipeline by Amal Therapeutics SA, H2 2016 114
Glioblastoma Multiforme (GBM) - Pipeline by Ambrx Inc, H2 2016 115
Glioblastoma Multiforme (GBM) - Pipeline by Amgen Inc, H2 2016 116
Glioblastoma Multiforme (GBM) - Pipeline by Ampio Pharmaceuticals Inc, H2 2016 117
Glioblastoma Multiforme (GBM) - Pipeline by AngioChem Inc, H2 2016 118
Glioblastoma Multiforme (GBM) - Pipeline by Apac Biotech Pvt Ltd, H2 2016 119
Glioblastoma Multiforme (GBM) - Pipeline by Apceth GmbH & Co KG, H2 2016 120
Glioblastoma Multiforme (GBM) - Pipeline by APIM Therapeutics AS, H2 2016 121
Glioblastoma Multiforme (GBM) - Pipeline by Apogenix GmbH, H2 2016 122
Glioblastoma Multiforme (GBM) - Pipeline by Ariad Pharmaceuticals Inc, H2 2016 123
Glioblastoma Multiforme (GBM) - Pipeline by Arog Pharmaceuticals Inc, H2 2016 124
Glioblastoma Multiforme (GBM) - Pipeline by Astellas Pharma Inc, H2 2016 125
Glioblastoma Multiforme (GBM) - Pipeline by AstraZeneca Plc, H2 2016 126
Glioblastoma Multiforme (GBM) - Pipeline by Athenex Inc, H2 2016 127
Glioblastoma Multiforme (GBM) - Pipeline by Axelar AB, H2 2016 128
Glioblastoma Multiforme (GBM) - Pipeline by Basilea Pharmaceutica Ltd, H2 2016 129
Glioblastoma Multiforme (GBM) - Pipeline by Batu Biologics Inc, H2 2016 130
Glioblastoma Multiforme (GBM) - Pipeline by Bayer AG, H2 2016 131
Glioblastoma Multiforme (GBM) - Pipeline by BeiGene Ltd, H2 2016 132
Glioblastoma Multiforme (GBM) - Pipeline by Bexion Pharmaceuticals LLC, H2 2016 133
Glioblastoma Multiforme (GBM) - Pipeline by BeyondSpring Pharmaceuticals Inc, H2 2016 134
Glioblastoma Multiforme (GBM) - Pipeline by Bio-Path Holdings Inc, H2 2016 135
Glioblastoma Multiforme (GBM) - Pipeline by Bioasis Technologies Inc, H2 2016 136
Glioblastoma Multiforme (GBM) - Pipeline by BioCancell Ltd, H2 2016 137
Glioblastoma Multiforme (GBM) - Pipeline by Biomar Microbial Technologies, H2 2016 138
Glioblastoma Multiforme (GBM) - Pipeline by Bioncotech Therapeutics SL, H2 2016 139
Glioblastoma Multiforme (GBM) - Pipeline by Biovista Inc, H2 2016 140
Glioblastoma Multiforme (GBM) - Pipeline by Boehringer Ingelheim GmbH, H2 2016 141
Glioblastoma Multiforme (GBM) - Pipeline by Boston Biomedical Inc, H2 2016 142
Glioblastoma Multiforme (GBM) - Pipeline by Bristol-Myers Squibb Company, H2 2016 143
Glioblastoma Multiforme (GBM) - Pipeline by BTG Plc, H2 2016 144
Glioblastoma Multiforme (GBM) - Pipeline by Cantex Pharmaceuticals Inc, H2 2016 145
Glioblastoma Multiforme (GBM) - Pipeline by Cavion LLC, H2 2016 146
Glioblastoma Multiforme (GBM) - Pipeline by Celgene Corp, H2 2016 147
Glioblastoma Multiforme (GBM) - Pipeline by Cell Medica Ltd, H2 2016 148
Glioblastoma Multiforme (GBM) - Pipeline by Celldex Therapeutics Inc, H2 2016 149
Glioblastoma Multiforme (GBM) - Pipeline by Celsion Corp, H2 2016 150
Glioblastoma Multiforme (GBM) - Pipeline by ChemoCentryx Inc, H2 2016 151
Glioblastoma Multiforme (GBM) - Pipeline by CLL Pharma SA, H2 2016 152
Glioblastoma Multiforme (GBM) - Pipeline by Coherus BioSciences Inc, H2 2016 153
Glioblastoma Multiforme (GBM) - Pipeline by Cortice Biosciences Inc, H2 2016 154
Glioblastoma Multiforme (GBM) - Pipeline by Critical Outcome Technologies Inc, H2 2016 155
Glioblastoma Multiforme (GBM) - Pipeline by CTI BioPharma Corp, H2 2016 156
Glioblastoma Multiforme (GBM) - Pipeline by Curadev Pharma Pvt Ltd, H2 2016 157
Glioblastoma Multiforme (GBM) - Pipeline by Cynata Therapeutics Limited, H2 2016 158
Glioblastoma Multiforme (GBM) - Pipeline by CytoVac A/S, H2 2016 159
Glioblastoma Multiforme (GBM) - Pipeline by CytRx Corp, H2 2016 160
Glioblastoma Multiforme (GBM) - Pipeline by Deciphera Pharmaceuticals LLC, H2 2016 161
Glioblastoma Multiforme (GBM) - Pipeline by DEKK-TEC Inc, H2 2016 162
Glioblastoma Multiforme (GBM) - Pipeline by DelMar Pharmaceuticals Inc, H2 2016 163
Glioblastoma Multiforme (GBM) - Pipeline by Diffusion Pharmaceuticals Inc, H2 2016 164
Glioblastoma Multiforme (GBM) - Pipeline by Dr. Reddy's Laboratories Ltd, H2 2016 165
Glioblastoma Multiforme (GBM) - Pipeline by Ecrins Therapeutics SAS, H2 2016 166
Glioblastoma Multiforme (GBM) - Pipeline by EirGenix Inc, H2 2016 167
Glioblastoma Multiforme (GBM) - Pipeline by Eisai Co Ltd, H2 2016 168
Glioblastoma Multiforme (GBM) - Pipeline by Eli Lilly and Company, H2 2016 169
Glioblastoma Multiforme (GBM) - Pipeline by EnGeneIC Ltd, H2 2016 170
Glioblastoma Multiforme (GBM) - Pipeline by EntreChem SL, H2 2016 171
Glioblastoma Multiforme (GBM) - Pipeline by ERC Belgium SA, H2 2016 172
Glioblastoma Multiforme (GBM) - Pipeline by Evotec AG, H2 2016 173
Glioblastoma Multiforme (GBM) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 174
Glioblastoma Multiforme (GBM) - Pipeline by FirstString Research Inc, H2 2016 175
Glioblastoma Multiforme (GBM) - Pipeline by Five Prime Therapeutics Inc, H2 2016 176
Glioblastoma Multiforme (GBM) - Pipeline by Gene Techno Science Co Ltd, H2 2016 177
Glioblastoma Multiforme (GBM) - Pipeline by Genentech Inc, H2 2016 178
Glioblastoma Multiforme (GBM) - Pipeline by Genisphere Inc, H2 2016 179
Glioblastoma Multiforme (GBM) - Pipeline by Genor BioPharma Co Ltd, H2 2016 180
Glioblastoma Multiforme (GBM) - Pipeline by Genzyme Corp, H2 2016 181
Glioblastoma Multiforme (GBM) - Pipeline by GlaxoSmithKline Plc, H2 2016 182
Glioblastoma Multiforme (GBM) - Pipeline by GtreeBNT Co Ltd, H2 2016 183
Glioblastoma Multiforme (GBM) - Pipeline by GW Pharmaceuticals Plc, H2 2016 184
Glioblastoma Multiforme (GBM) - Pipeline by Hamlet Pharma AB, H2 2016 185
Glioblastoma Multiforme (GBM) - Pipeline by Hutchison MediPharma Ltd, H2 2016 186
Glioblastoma Multiforme (GBM) - Pipeline by Immatics Biotechnologies GmbH, H2 2016 187
Glioblastoma Multiforme (GBM) - Pipeline by Immune Pharmaceuticals Inc, H2 2016 188
Glioblastoma Multiforme (GBM) - Pipeline by ImmunoCellular Therapeutics Ltd, H2 2016 189
Glioblastoma Multiforme (GBM) - Pipeline by Immunomedics Inc, H2 2016 190
Glioblastoma Multiforme (GBM) - Pipeline by Immunomet Therapeutics Inc, H2 2016 191
Glioblastoma Multiforme (GBM) - Pipeline by Immunomic Therapeutics Inc, H2 2016 192
Glioblastoma Multiforme (GBM) - Pipeline by Immupharma Plc, H2 2016 193
Glioblastoma Multiforme (GBM) - Pipeline by Incuron LLC, H2 2016 194
Glioblastoma Multiforme (GBM) - Pipeline by Incyte Corp, H2 2016 195
Glioblastoma Multiforme (GBM) - Pipeline by Infinity Pharmaceuticals Inc, H2 2016 196
Glioblastoma Multiforme (GBM) - Pipeline by Inspyr Therapeutics Inc, H2 2016 197
Glioblastoma Multiforme (GBM) - Pipeline by INSYS Therapeutics Inc, H2 2016 198
Glioblastoma Multiforme (GBM) - Pipeline by Intica Biomedical Inc, H2 2016 199
Glioblastoma Multiforme (GBM) - Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H2 2016 200
Glioblastoma Multiforme (GBM) - Pipeline by Johnson & Johnson, H2 2016 201
Glioblastoma Multiforme (GBM) - Pipeline by Kadmon Corp LLC, H2 2016 202
Glioblastoma Multiforme (GBM) - Pipeline by Kalgene Pharmaceuticals Inc, H2 2016 203
Glioblastoma Multiforme (GBM) - Pipeline by KaloBios Pharmaceuticals Inc, H2 2016 204
Glioblastoma Multiforme (GBM) - Pipeline by Karyopharm Therapeutics Inc, H2 2016 205
Glioblastoma Multiforme (GBM) - Pipeline by Kite Pharma Inc, H2 2016 206
Glioblastoma Multiforme (GBM) - Pipeline by Komipharm International Co Ltd, H2 2016 207
Glioblastoma Multiforme (GBM) - Pipeline by Lentigen Technology Inc, H2 2016 208
Glioblastoma Multiforme (GBM) - Pipeline by Les Laboratoires Servier SAS, H2 2016 209
Glioblastoma Multiforme (GBM) - Pipeline by LinXis BV, H2 2016 210
Glioblastoma Multiforme (GBM) - Pipeline by Lion Biotechnologies Inc, H2 2016 211
Glioblastoma Multiforme (GBM) - Pipeline by Lixte Biotechnology Holdings Inc, H2 2016 212
Glioblastoma Multiforme (GBM) - Pipeline by Loxo Oncology, Inc., H2 2016 213
Glioblastoma Multiforme (GBM) - Pipeline by Mabion SA, H2 2016 214
Glioblastoma Multiforme (GBM) - Pipeline by MacroGenics Inc, H2 2016 215
Glioblastoma Multiforme (GBM) - Pipeline by Mateon Therapeutics Inc, H2 2016 216
Glioblastoma Multiforme (GBM) - Pipeline by Medicenna Therapeutics Inc, H2 2016 217
Glioblastoma Multiforme (GBM) - Pipeline by MedImmune LLC, H2 2016 218
Glioblastoma Multiforme (GBM) - Pipeline by Merck & Co Inc, H2 2016 219
Glioblastoma Multiforme (GBM) - Pipeline by Merck KGaA, H2 2016 220
Glioblastoma Multiforme (GBM) - Pipeline by Midatech Pharma Plc, H2 2016 221
Glioblastoma Multiforme (GBM) - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 222
Glioblastoma Multiforme (GBM) - Pipeline by MimiVax LLC, H2 2016 223
Glioblastoma Multiforme (GBM) - Pipeline by Moleculin Biotech Inc, H2 2016 224
Glioblastoma Multiforme (GBM) - Pipeline by Mycenax Biotech Inc, H2 2016 225
Glioblastoma Multiforme (GBM) - Pipeline by Nanomerics Ltd, H2 2016 226
Glioblastoma Multiforme (GBM) - Pipeline by Neonc Technologies Inc, H2 2016 227
Glioblastoma Multiforme (GBM) - Pipeline by Nerviano Medical Sciences Srl, H2 2016 228
Glioblastoma Multiforme (GBM) - Pipeline by Neumedicines Inc, H2 2016 229
Glioblastoma Multiforme (GBM) - Pipeline by Neuralstem Inc, H2 2016 230
Glioblastoma Multiforme (GBM) - Pipeline by NewLink Genetics Corp, H2 2016 231
Glioblastoma Multiforme (GBM) - Pipeline by Northwest Biotherapeutics Inc, H2 2016 232
Glioblastoma Multiforme (GBM) - Pipeline by Novartis AG, H2 2016 233
Glioblastoma Multiforme (GBM) - Pipeline by Novogen Ltd, H2 2016 234
Glioblastoma Multiforme (GBM) - Pipeline by Noxxon Pharma AG, H2 2016 235
Glioblastoma Multiforme (GBM) - Pipeline by Nuo Therapeutics Inc, H2 2016 236
Glioblastoma Multiforme (GBM) - Pipeline by NuvOx Pharma LLC, H2 2016 237
Glioblastoma Multiforme (GBM) - Pipeline by Omniox Inc, H2 2016 238
Glioblastoma Multiforme (GBM) - Pipeline by Oncobiologics Inc, H2 2016 239
Glioblastoma Multiforme (GBM) - Pipeline by Oncodesign SA, H2 2016 240
Glioblastoma Multiforme (GBM) - Pipeline by Onconova Therapeutics Inc, H2 2016 241
Glioblastoma Multiforme (GBM) - Pipeline by Oncternal Therapeutics Inc, H2 2016 242
Glioblastoma Multiforme (GBM) - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 243
Glioblastoma Multiforme (GBM) - Pipeline by Orphagen Pharmaceuticals Inc, H2 2016 244
Glioblastoma Multiforme (GBM) - Pipeline by Orphit SAS, H2 2016 245
Glioblastoma Multiforme (GBM) - Pipeline by Oryx GmbH & Co KG, H2 2016 246
Glioblastoma Multiforme (GBM) - Pipeline by Peloton Therapeutics Inc, H2 2016 247
Glioblastoma Multiforme (GBM) - Pipeline by Peregrine Pharmaceuticals Inc, H2 2016 248
Glioblastoma Multiforme (GBM) - Pipeline by Pfizer Inc, H2 2016 249
Glioblastoma Multiforme (GBM) - Pipeline by PharmAbcine Inc, H2 2016 250
Glioblastoma Multiforme (GBM) - Pipeline by PharmaCyte Biotech Inc, H2 2016 251
Glioblastoma Multiforme (GBM) - Pipeline by Pharmicell Co Ltd, H2 2016 252
Glioblastoma Multiforme (GBM) - Pipeline by PIQUR Therapeutics AG, H2 2016 253
Glioblastoma Multiforme (GBM) - Pipeline by Plex Pharmaceuticals Inc, H2 2016 254
Glioblastoma Multiforme (GBM) - Pipeline by Plexxikon Inc, H2 2016 255
Glioblastoma Multiforme (GBM) - Pipeline by Prana Biotechnology Ltd, H2 2016 256
Glioblastoma Multiforme (GBM) - Pipeline by Progenics Pharmaceuticals Inc, H2 2016 257
Glioblastoma Multiforme (GBM) - Pipeline by Puma Biotechnology Inc, H2 2016 258
Glioblastoma Multiforme (GBM) - Pipeline by Recepta Biopharma SA, H2 2016 259
Glioblastoma Multiforme (GBM) - Pipeline by Regulus Therapeutics Inc, H2 2016 260
Glioblastoma Multiforme (GBM) - Pipeline by ReNeuron Group Plc, H2 2016 261
Glioblastoma Multiforme (GBM) - Pipeline by Rexahn Pharmaceuticals Inc, H2 2016 262
Glioblastoma Multiforme (GBM) - Pipeline by Rgenix Inc, H2 2016 263
Glioblastoma Multiforme (GBM) - Pipeline by Richter Gedeon Nyrt, H2 2016 264
Glioblastoma Multiforme (GBM) - Pipeline by Rigontec GmbH, H2 2016 265
Glioblastoma Multiforme (GBM) - Pipeline by Sanofi, H2 2016 266
Glioblastoma Multiforme (GBM) - Pipeline by Sapience Therapeutics Inc, H2 2016 267
Glioblastoma Multiforme (GBM) - Pipeline by Scancell Holdings Plc, H2 2016 268
Glioblastoma Multiforme (GBM) - Pipeline by Sellas Inc, H2 2016 269
Glioblastoma Multiforme (GBM) - Pipeline by Sigma-Tau SpA, H2 2016 270
Glioblastoma Multiforme (GBM) - Pipeline by SignPath Pharma Inc, H2 2016 271
Glioblastoma Multiforme (GBM) - Pipeline by SOM Biotech SL, H2 2016 272
Glioblastoma Multiforme (GBM) - Pipeline by Sorrento Therapeutics Inc, H2 2016 273
Glioblastoma Multiforme (GBM) - Pipeline by StemGen SpA, H2 2016 274
Glioblastoma Multiforme (GBM) - Pipeline by Stemline Therapeutics Inc, H2 2016 275
Glioblastoma Multiforme (GBM) - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016 276
Glioblastoma Multiforme (GBM) - Pipeline by Susavion Biosciences Inc, H2 2016 277
Glioblastoma Multiforme (GBM) - Pipeline by Symphogen A/S, H2 2016 278
Glioblastoma Multiforme (GBM) - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016 279
Glioblastoma Multiforme (GBM) - Pipeline by Terpenoid Therapeutics Inc, H2 2016 280
Glioblastoma Multiforme (GBM) - Pipeline by Therapeia GmbH & Co KG, H2 2016 281
Glioblastoma Multiforme (GBM) - Pipeline by Theravectys SA, H2 2016 282
Glioblastoma Multiforme (GBM) - Pipeline by Threshold Pharmaceuticals Inc, H2 2016 283
Glioblastoma Multiforme (GBM) - Pipeline by Tocagen Inc, H2 2016 284
Glioblastoma Multiforme (GBM) - Pipeline by TRACON Pharmaceuticals Inc, H2 2016 285
Glioblastoma Multiforme (GBM) - Pipeline by Transgene SA, H2 2016 286
Glioblastoma Multiforme (GBM) - Pipeline by Trillium Therapeutics Inc, H2 2016 287
Glioblastoma Multiforme (GBM) - Pipeline by TVAX Biomedical Inc, H2 2016 288
Glioblastoma Multiforme (GBM) - Pipeline by Tyme Technologies Inc, H2 2016 289
Glioblastoma Multiforme (GBM) - Pipeline by Upsher-Smith Laboratories Inc, H2 2016 290
Glioblastoma Multiforme (GBM) - Pipeline by Vascular Biogenics Ltd, H2 2016 291
Glioblastoma Multiforme (GBM) - Pipeline by Vault Pharma Inc, H2 2016 292
Glioblastoma Multiforme (GBM) - Pipeline by Vaximm AG, H2 2016 293
Glioblastoma Multiforme (GBM) - Pipeline by VBI Vaccines Inc, H2 2016 294
Glioblastoma Multiforme (GBM) - Pipeline by VCN Biosciences SL, H2 2016 295
Glioblastoma Multiforme (GBM) - Pipeline by Vertex Pharmaceuticals Inc, H2 2016 296
Glioblastoma Multiforme (GBM) - Pipeline by ViraTherapeutics GmbH, H2 2016 297
Glioblastoma Multiforme (GBM) - Pipeline by Virttu Biologics Ltd, H2 2016 298
Glioblastoma Multiforme (GBM) - Pipeline by Vyriad Inc, H2 2016 299
Glioblastoma Multiforme (GBM) - Pipeline by X4 Pharmaceuticals Inc, H2 2016 300
Glioblastoma Multiforme (GBM) - Pipeline by ZIOPHARM Oncology Inc, H2 2016 301
Assessment by Monotherapy Products, H2 2016 302
Assessment by Combination Products, H2 2016 303
Number of Products by Stage and Target, H2 2016 305
Number of Products by Stage and Mechanism of Action, H2 2016 323
Number of Products by Stage and Route of Administration, H2 2016 341
Number of Products by Stage and Molecule Type, H2 2016 343
Glioblastoma Multiforme (GBM) - Dormant Projects, H2 2016 1284
Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..1), H2 2016 1285
Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..2), H2 2016 1286
Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..3), H2 2016 1287
Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..4), H2 2016 1288
Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..5), H2 2016 1289
Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..6), H2 2016 1290
Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..7), H2 2016 1291
Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..8), H2 2016 1292
Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..9), H2 2016 1293
Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..10), H2 2016 1294
Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..11), H2 2016 1295
Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..12), H2 2016 1296
Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..13), H2 2016 1297
Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..14), H2 2016 1298
Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..15), H2 2016 1299
Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..16), H2 2016 1300
Glioblastoma Multiforme (GBM) - Discontinued Products, H2 2016 1301
Glioblastoma Multiforme (GBM) - Discontinued Products (Contd..1), H2 2016 1302
Glioblastoma Multiforme (GBM) - Discontinued Products (Contd..2), H2 2016 1303

List of Figures
Number of Products under Development for Glioblastoma Multiforme (GBM), H2 2016 54
Number of Products under Development for Glioblastoma Multiforme (GBM) - Comparative Analysis, H2 2016 55
Number of Products under Development by Companies, H2 2016 56
Number of Products under Investigation by Universities/Institutes, H2 2016 74
Comparative Analysis by Late Stage Development, H2 2016 77
Comparative Analysis by Clinical Stage Development, H2 2016 78
Comparative Analysis by Early Stage Products, H2 2016 79
Assessment by Monotherapy Products, H2 2016 302
Assessment by Combination Products, H2 2016 303
Number of Products by Top 10 Targets, H2 2016 304
Number of Products by Stage and Top 10 Targets, H2 2016 304
Number of Products by Top 10 Mechanism of Actions, H2 2016 322
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 322
Number of Products by Top 10 Routes of Administration, H2 2016 340
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 340
Number of Products by Top 10 Molecule Types, H2 2016 342
Number of Products by Stage and Top 10 Molecule Types, H2 2016 342

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *